Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9HER2 Positive Metastatic Breast Cancer 2Non-squamous NSCLC 1Locally Advanced Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1HER2+ Breast Cancer 1Breast Cancer Invasive 1

Interventions

spartalizumab 1sintilimab 1pyrotinib 1pertuzumab 1palbociclib 1Trastuzumab 1Taxes 1Letrozole 1Everolimus 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2+ Breast Cancer × pyrotinib × Clear all
NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡